Moneycontrol Bureau
Marksans Pharma's third quarter consolidated net profit surged 23.7 percent year-on-year to Rs 27.7 crore led by strong revenue.
Total income of the pharma company jumped 28 percent to Rs 213.3 crore during October-December quarter from Rs 166.7 crore in same quarter last fiscal.
Finance cost climbed sharply to Rs 6.34 crore from Rs 2.84 crore and tax expenses rose to Rs 13.71 crore from Rs 3.97 crore during the same period.
In first nine months period of FY15, consolidated profit grew 37.65 percent Y-o-Y to Rs 84.35 crore and revenue shot up 32.15 percent to Rs 626.27 crore, driven by strong UK and US sales.
Europe, UK formulations business reported a 33 percent growth Y-o-Y at Rs 400.7 crore and US & North America business grew 81.29 percent to Rs 119.74 crore during April-December.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
